Compare QDEL & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QDEL | KURA |
|---|---|---|
| Founded | 1979 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 989.5M | 912.7M |
| IPO Year | 2022 | 2015 |
| Metric | QDEL | KURA |
|---|---|---|
| Price | $10.73 | $7.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 16 |
| Target Price | $15.00 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 2.2M | 2.2M |
| Earning Date | 11-03-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.35 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,730,200,000.00 | $67,482,000.00 |
| Revenue This Year | N/A | $33.60 |
| Revenue Next Year | N/A | $122.30 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 25.24 |
| 52 Week Low | $9.92 | $6.75 |
| 52 Week High | $35.58 | $13.90 |
| Indicator | QDEL | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 37.87 | 36.55 |
| Support Level | $10.49 | $7.36 |
| Resistance Level | $18.15 | $9.82 |
| Average True Range (ATR) | 1.25 | 0.79 |
| MACD | -0.37 | -0.12 |
| Stochastic Oscillator | 7.55 | 23.54 |
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.